Key Stats for Eli Lilly Stock
- Price change for Eli Lilly stock: 3.8%
- $LLY Stock Price as of Apr. 1: $955
- 52-Week High: $1134
- $LLY Stock Price Target: $1209
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock is moving higher after the FDA approved Foundayo, the company’s once-daily GLP-1 weight loss pill.
The drug is already shipping (from this week) through Lilly’s direct-to-consumer platform LillyDirect, with pharmacy availability coming shortly after.
Pricing is aggressive.
- Insured patients can get Foundayo for as little as $25 a month with a Lilly coupon.
- Cash-pay customers will pay between $149 and $349, depending on dose.
- That matches the entry price of Novo Nordisk’s competing Wegovy pill, setting up a direct price battle between the two GLP-1 giants.
- Foundayo isn’t as powerful as Lilly’s injectable Zepbound, which has shown an average body weight loss of over 20% in trials.
- Foundayo came in at around 12.4% in its late-stage study.
- But CEO Dave Ricks sees the pill filling a different role — easier access, no injection required, and no food or water restrictions at dosing time.
- Novo’s Wegovy pill must be taken on an empty stomach with minimal water.
Analysts estimate Foundayo could reach nearly $15 billion in annual sales by 2030, though that still trails expectations for Zepbound and Mounjaro.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
Eli Lilly stock has been under pressure this year, down about 12%, after a historic run that briefly made it the first trillion-dollar healthcare company.
A strong Foundayo launch is seen as critical to turning that around.
Eli Lilly stock will likely be judged on prescription data in the coming weeks. If early script numbers hold up, analysts expect investors to look past any near-term earnings noise.
A key retatrutide weight loss trial readout later this year could be another catalyst for Eli Lilly stock.
The oral GLP-1 market is expanding fast.
Early data from Novo’s pill launch showed more than 600,000 prescriptions in March — mostly new patients, not people switching from shots.
If that pattern holds for Foundayo, Eli Lilly stock could have real momentum heading into the back half of the year.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
